PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

By C. Blank, I. Brown, A. Peterson, M. Spiotto, Yoshiko Iwai, Tasuku Honjo, T. Gajewski. Cancer Research, 2004

757 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/b0c7b0e0bfae996048827e7ca4c946aadccea28a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Pardoll
2. W. Zou
3. George Coukos
4. T. Gajewski
5. S. Spranger
6. G. Freeman
7. T. Welling
8. Joel Crespo

In Oncology

1. W. Zou
2. D. Pardoll
3. T. Gajewski
4. G. Freeman
5. S. Spranger
6. T. Welling
7. Zhigang Tian
8. George Coukos

Citations in the corpus

• STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors (2014, neutral): “SIY tumors (Blank et al., 2004).”
• IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer (2015, background): “Interferon-g is also known to upregulate PD-L1 expression on tumour cells (Blank et al, 2004).”
• Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (2013, neutral): “BRAF inhibitor 4 (10) 0 1 (4) 4 (12) 1 (5) 10 (7)”